Candida albicans

3MB-PP1 is a bulky purine analog and a Polo-like kinase 1 (Plk1) inhibitor. In cells expressing analog-sensitive Plk1 alleles, 3MB-PP1 blocks mitotic progression and cell division arise by targeting Plk1. 3MB-PP1 specifically inhibits analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase with IC50 of 2 μM. 3MB-PP1 can be used for the research of cell division and hypha formation of Candida albicans.

Inz-1 is an effective and fungal-selective inhibitor of mitochondrial cytochrome bc1 with IC50s of 8.092 and 45.320 μM for yeast and human. Inz-1 reverses Fluconazole or other triazole antifungals' resistance in the pathogenic fungus Candida albicans.

2-Phenylethanol (Phenylethanol) is an antimicrobial, antiseptic, and disinfectant. It is used also as an aromatic essence and preservative in pharmaceutics and perfumery.

Fluconazole (UK-49858) is a triazole antifungal agent used to treat oropharyngeal candidiasis and cryptococcal meningitis in AIDS.

Nystatin (Fungicidin) is a topical and oral antifungal agent with activity against many species of yeast and candida albicans, which is used largely to treat skin and oropharyngeal candidiasis.

Tebuconazole is an agricultural azole fungicide. It can also inhibit CYP51 (IC50s: 0.9 and 1.3 μM for Candida albicans CYP51 and truncated Homo sapiens CYP51, respectively).

2,6-Dichlorodiphenylamine, an analogue of Diclofenac Sodium, exhibits anti-Candida albicans activity. Diclofenac Sodium, a potent and nonselective COX inhibitor, has IC50 values of 4 and 1.3 nM for human COX-1 and COX-2 in CHO cells. [1]. Makoto Urai, et al. Potent Drugs That Attenuate anti-Candida albicans Activity of Fluconazole and Their Possible Mechanisms of Action. J Infect Chemother. 2014 Oct;20(10):612-5.

1-(4-AMinophenyl)-5,6-dihydro-3-(4-Morpholinyl)-2(1h)-pyridinone has broad-spectrum antifungal activity with inhibitory effects on Candida albicans, Aspergillus niger, Pseudomonas aeruginosa and Staphylococcus aureus.

Filastatin is a durable inhibitor of Candida albicans filamentation and exhibits potent antifungal activity.

Oteseconazole (VT-1161) is an orally active anti-fungal agent. Oteseconazole displays no obvious effect on human CYP51. It also potently binds to and inhibits Candida albicans CYP51 (Kd, <39 nM).

Amphotericin X1 is a derivative of Amphotericin B with good antifungal activity. Amphotericin X1 inhibits Candida albicans 33 079, Cryptococcus neoformans 451, C.parapsilosis 937A, Aspergillus niger 57A and A.fumigatus (MICs: 1 μg mL, 1 μg mL, 8 μg mL, 2

N-563 promotes resistance to Candida albicans infection in mice

Anandamide ((5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide), an immune modulator, acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18 GPR55) in the central nervous system.

Cyclo-L-Trp-L-Trp is a broad-spectrum antifungal. It also induces a high degree of acetylation of histones.

CYP51-IN-20 (compound 5b), an antifungal agent, effectively inhibits CYP51 and exhibits significant activity against Candida albicans ATCC 10231. It suppresses the ERG11 (Cyp51) gene expression and markedly curtails the morphological transformation from yeast to hyphae. Furthermore, when combined with Voriconazole, CYP51-IN-20 synergistically occupies the entire CYP51 binding site, enhancing its inhibitory impact in the Glechoma moth model.

14α-Demethylase-IN-1 (compound 2e) is an inhibitor of 14α-demethylase and serves as an antifungal agent. For Candida albicans, Candida parapsilosis, Candida krusei, and Candida glabrata, the MIC50 values recorded at 48 hours are 2.47 μM, 1.23 μM, 19.70 μM, and 19.70 μM respectively.

Antifungalagent 112 (Compound 1e) exhibits antifungal activity against Candida albicans, Aspergillus niger, and Aspergillus fumigatus, with minimum inhibitory concentrations (MIC) of 0.0024 M, 0.0022 M, and 0.0028 M, respectively.

CYP51-IN-9 (compound 1i) is an analog of Fluconazole and serves as an effective antifungal agent. It exhibits a MIC80 of 62.5 ng mL against Microsporum gypseum and Candida albicans, indicating potent inhibitory activity.

CYP51-IN-12 (compound 1l), an analog of Fluconazole, serves as an effective antifungal agent. It inhibits Microsporum gypseum and Candida albicans with a MIC80 of 15.6 ng mL.

CYP51-IN-7 (compound 1g) is an analogue of Fluconazole and serves as an effective antifungal agent. It exhibits inhibitory activity against Microsporum gypseum and Candida albicans, with MIC80 values of 62.5 ng mL and 250 ng mL, respectively.

CYP51-IN-14 (compound 1n), a derivative of Fluconazole, functions as an effective antifungal agent. This compound inhibits Microsporum gypseum and Candida albicans with a minimum inhibitory concentration (MIC80) of 1 μg mL.

CYP51-IN-13 (compound 1m), a fluconazole analog, serves as an effective antifungal agent. It inhibits Microsporum gypseum and Candida albicans with MIC80 values of 62.5 ng mL and 250 ng mL, respectively.

CYP51-IN-4 (compound 1d), an analog of Fluconazole, serves as an effective antifungal agent. It inhibits Microsporum gypseum and Candida albicans with an MIC80 of 15.6 ng mL.

CYP51-IN-8 (compound 1h), an analog of Fluconazole, serves as an effective antifungal agent. It inhibits Microsporum gypseum and Candida albicans with MIC80 values of 15.6 and 62.5 ng mL, respectively.